compounding semaglutide enforcement news today Feds warn telehealth companies about "illegal marketing" of compounded GLP-1s New Novo Nordisk initiatives support

Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial

In addition, an active (glipizide)-controlled trial of 52-weeks duration was conducted in 1,172 patients with type 2 diabetes mellitus who had inadequate glycemic control on metformin

This study aimed to perform a systematic review to identify the evidence relating the effects of GLP-1 RAs on neurological complications of diabetes (stroke, cognitive impairment, and peripheral neuropathy)

Compounded semaglutide is not FDA-approved and carries quality and safety risks

With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP1 receptor agonists Read More